A randomized, double-blind, placebo-controlled multicenter study for evaluating the effects of fixed-dose combinations of vitamin C, vitamin E, lysozyme, and carbazochrome on gingival inflammation in chronic periodontitis patients

Ji Youn Hong, Jung Seok Lee, Seong Ho Choi, Hyun Seung Shin, Jung Chul Park, Seung Il Shin, Jong Hyuk Chung

Research output: Contribution to journalArticle

Abstract

Background: To evaluate gingival inflammation from fixed-dose combinations of vitamin C, vitamin E, lysozyme and carbazochrome (CELC) in the treatment of chronic periodontitis following scaling and root planing. Methods: One hundred patients were randomly assigned to receive CELC (test) or placebo (control) for the first 4 weeks at a 1:1 ratio, and both groups received CELC for the remaining 4 weeks. Primary outcome was the mean change in the gingival index (GI) after 4 weeks. Secondary outcomes included mean change in GI after 8 weeks and plaque index, probing depth, clinical attachment level, and VAS at 4 weeks and 8 weeks. Results: Ninety-three patients completed the study. The GI in the test group significantly decreased after 4 weeks (p < 0.001) and 8 weeks (p < 0.001). The mean change from baseline in GI significantly decreased in the test group compared to the control group after 4 weeks (p = 0.015). In the GEE model adjusting for age, gender and visits, the test group showed 2.5 times GI improvement compared to the control group (p = 0.022). Conclusions: Within the study, CELC showed a significant reduction in gingival inflammation compared with a placebo. Other parameters, however, were similar between groups. Trial registration: KCT0001366 (Clinical Research Information Service, Republic of Korea) and 29 Jan 2015, retrospectively registered.

Original languageEnglish
Article number40
JournalBMC Oral Health
Volume19
Issue number1
DOIs
Publication statusPublished - 2019 Mar 7

Fingerprint

Periodontal Index
Chronic Periodontitis
Muramidase
Vitamin E
Ascorbic Acid
Multicenter Studies
Placebos
Inflammation
Root Planing
Republic of Korea
Control Groups
Information Services
carbazochrome
Research

All Science Journal Classification (ASJC) codes

  • Dentistry(all)

Cite this

@article{13aadacc0de24e93b6542c64628c2c1a,
title = "A randomized, double-blind, placebo-controlled multicenter study for evaluating the effects of fixed-dose combinations of vitamin C, vitamin E, lysozyme, and carbazochrome on gingival inflammation in chronic periodontitis patients",
abstract = "Background: To evaluate gingival inflammation from fixed-dose combinations of vitamin C, vitamin E, lysozyme and carbazochrome (CELC) in the treatment of chronic periodontitis following scaling and root planing. Methods: One hundred patients were randomly assigned to receive CELC (test) or placebo (control) for the first 4 weeks at a 1:1 ratio, and both groups received CELC for the remaining 4 weeks. Primary outcome was the mean change in the gingival index (GI) after 4 weeks. Secondary outcomes included mean change in GI after 8 weeks and plaque index, probing depth, clinical attachment level, and VAS at 4 weeks and 8 weeks. Results: Ninety-three patients completed the study. The GI in the test group significantly decreased after 4 weeks (p < 0.001) and 8 weeks (p < 0.001). The mean change from baseline in GI significantly decreased in the test group compared to the control group after 4 weeks (p = 0.015). In the GEE model adjusting for age, gender and visits, the test group showed 2.5 times GI improvement compared to the control group (p = 0.022). Conclusions: Within the study, CELC showed a significant reduction in gingival inflammation compared with a placebo. Other parameters, however, were similar between groups. Trial registration: KCT0001366 (Clinical Research Information Service, Republic of Korea) and 29 Jan 2015, retrospectively registered.",
author = "Hong, {Ji Youn} and Lee, {Jung Seok} and Choi, {Seong Ho} and Shin, {Hyun Seung} and Park, {Jung Chul} and Shin, {Seung Il} and Chung, {Jong Hyuk}",
year = "2019",
month = "3",
day = "7",
doi = "10.1186/s12903-019-0728-2",
language = "English",
volume = "19",
journal = "BMC Oral Health",
issn = "1472-6831",
publisher = "BioMed Central",
number = "1",

}

A randomized, double-blind, placebo-controlled multicenter study for evaluating the effects of fixed-dose combinations of vitamin C, vitamin E, lysozyme, and carbazochrome on gingival inflammation in chronic periodontitis patients. / Hong, Ji Youn; Lee, Jung Seok; Choi, Seong Ho; Shin, Hyun Seung; Park, Jung Chul; Shin, Seung Il; Chung, Jong Hyuk.

In: BMC Oral Health, Vol. 19, No. 1, 40, 07.03.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A randomized, double-blind, placebo-controlled multicenter study for evaluating the effects of fixed-dose combinations of vitamin C, vitamin E, lysozyme, and carbazochrome on gingival inflammation in chronic periodontitis patients

AU - Hong, Ji Youn

AU - Lee, Jung Seok

AU - Choi, Seong Ho

AU - Shin, Hyun Seung

AU - Park, Jung Chul

AU - Shin, Seung Il

AU - Chung, Jong Hyuk

PY - 2019/3/7

Y1 - 2019/3/7

N2 - Background: To evaluate gingival inflammation from fixed-dose combinations of vitamin C, vitamin E, lysozyme and carbazochrome (CELC) in the treatment of chronic periodontitis following scaling and root planing. Methods: One hundred patients were randomly assigned to receive CELC (test) or placebo (control) for the first 4 weeks at a 1:1 ratio, and both groups received CELC for the remaining 4 weeks. Primary outcome was the mean change in the gingival index (GI) after 4 weeks. Secondary outcomes included mean change in GI after 8 weeks and plaque index, probing depth, clinical attachment level, and VAS at 4 weeks and 8 weeks. Results: Ninety-three patients completed the study. The GI in the test group significantly decreased after 4 weeks (p < 0.001) and 8 weeks (p < 0.001). The mean change from baseline in GI significantly decreased in the test group compared to the control group after 4 weeks (p = 0.015). In the GEE model adjusting for age, gender and visits, the test group showed 2.5 times GI improvement compared to the control group (p = 0.022). Conclusions: Within the study, CELC showed a significant reduction in gingival inflammation compared with a placebo. Other parameters, however, were similar between groups. Trial registration: KCT0001366 (Clinical Research Information Service, Republic of Korea) and 29 Jan 2015, retrospectively registered.

AB - Background: To evaluate gingival inflammation from fixed-dose combinations of vitamin C, vitamin E, lysozyme and carbazochrome (CELC) in the treatment of chronic periodontitis following scaling and root planing. Methods: One hundred patients were randomly assigned to receive CELC (test) or placebo (control) for the first 4 weeks at a 1:1 ratio, and both groups received CELC for the remaining 4 weeks. Primary outcome was the mean change in the gingival index (GI) after 4 weeks. Secondary outcomes included mean change in GI after 8 weeks and plaque index, probing depth, clinical attachment level, and VAS at 4 weeks and 8 weeks. Results: Ninety-three patients completed the study. The GI in the test group significantly decreased after 4 weeks (p < 0.001) and 8 weeks (p < 0.001). The mean change from baseline in GI significantly decreased in the test group compared to the control group after 4 weeks (p = 0.015). In the GEE model adjusting for age, gender and visits, the test group showed 2.5 times GI improvement compared to the control group (p = 0.022). Conclusions: Within the study, CELC showed a significant reduction in gingival inflammation compared with a placebo. Other parameters, however, were similar between groups. Trial registration: KCT0001366 (Clinical Research Information Service, Republic of Korea) and 29 Jan 2015, retrospectively registered.

UR - http://www.scopus.com/inward/record.url?scp=85062594733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062594733&partnerID=8YFLogxK

U2 - 10.1186/s12903-019-0728-2

DO - 10.1186/s12903-019-0728-2

M3 - Article

C2 - 30845920

AN - SCOPUS:85062594733

VL - 19

JO - BMC Oral Health

JF - BMC Oral Health

SN - 1472-6831

IS - 1

M1 - 40

ER -